A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

Summary

The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.

Timeline

Start

2026-08-27

Primary completion

2029-03-30

Completion

2029-12-31

Drugs

Indications